NCT03932331 - Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies | Biotech Hunter

Enrollment

105

Participants

Timeline

Start Date

April 29, 2020

Primary Completion Date

December 22, 2022

Study Completion Date

June 24, 2026

Conditions

Phase I: Relapsed or Refractory B-cell MalignanciesPhase II Cohort A: Relapsed or Refractory Mantle Cell LymphomaPhase II Cohort B: Relapsed or Refractory Chronic Lymphocytic Leukemia

Interventions

DRUG

Acalabrutinib

Acalabrutinib 100 mg orally twice daily

Trial Locations (23)

10050

Research Site, Hohhot

100044

Research Site, Beijing

100142

Research Site, Beijing

100191

Research Site, Beijing

130021

Research Site, Changchun

150049

Research Site, Harbin

200032

Research Site, Shanghai

210029

Research Site, Nanjing

215006

Research Site, Suzhou

230031

Research Site, Hefei

272100

Research Site, Changzhou

300020

Research Site, Tianjin

300060

Research Site, Tianjin

310003

Research Site, Hangzhou

310022

Research Site, Hangzhou

330006

Research Site, Nanchang

410008

Research Site, Changsha

450008

Research Site, Zhengzhou

570311

Research Site, Haikou

610041

Research Site, Chengdu

810007

Research Site, Xining

830054

Research Site, Ürümqi

Unknown

Research Site, Fuzhou